GlassScriptPhysician profile
Albert Castro Marcano
NPI 1861572562
$15,333.19
in general payments reported to CMS, 2019-2025
38 companies · $4,423 in 2025
The $4,423 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,518 · 2022: $2,998 · 2023: $3,058 · 2024: $2,337 · 2025: $4,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,817.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,283.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,069.02 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $1,423.56 | 2021-2025 | |
| Novo Nordisk INC | $1,284.35 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $1,043.73 | 2021-2025 | Repatha, Krystexxa, Otezla |
| Esperion Therapeutics, INC. | $633.26 | 2021-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $563.14 | 2021-2025 | Belsomra, Gardasil 9, Capvaxive |
| Pfizer INC. | $544.74 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.84 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $454.02 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Sumitomo Pharma America, INC. | $279.74 | 2023-2025 | Gemtesa |
| Ardelyx, INC. | $278.56 | 2024-2025 | Ibsrela |
| Amarin Pharma, INC. | $273.95 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $258.84 | 2021-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $191.03 | 2024-2025 | Voquezna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $175.68 | 2025 | Symbravo |
| Lundbeck LLC | $169.24 | 2024-2025 | Vyepti |
| Janssen Pharmaceuticals, INC | $166.66 | 2021-2022 | |
| Medtronic, INC. | $156.66 | 2021 | |
| Sunovion Pharmaceuticals INC. | $152.06 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $144.66 | 2022-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $139.14 | 2025 | Veozah |
| Zimmer Biomet Holdings, INC. | $130.50 | 2021-2022 | |
| Horizon Therapeutics Plc | $126.02 | 2021-2022 | |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $124.47 | 2021-2023 | |
| Intuity Medical INC | $114.14 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amryt Pharma Holdings LTD | $99.99 | 2023 | Mycapssa |
| Redhill Biopharma INC. | $93.85 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.94 | 2021-2022 | |
| Vistapharm, INC. | $42.50 | 2021 | |
| Intra-Sana Laboratories | $34.84 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Glaxosmithkline, LLC. | $33.56 | 2021-2025 | Shingrix, Arexvy |
| Vertex Pharmaceuticals Incorporated | $30.71 | 2025 | |
| Cequr Corporation | $26.25 | 2024 | Cequr Simplicity |
| Advanced Oxygen Therapy INC. | $23.28 | 2023 | Topical Oxygen Chamber For Extremities |
| Incyte Corporation | $22.88 | 2025 | Opzelura |
| Corium, LLC | $19.38 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Marcano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.